Nivobotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Axillary Hyperhidrosis. According to GlobalData, Phase III drugs for Axillary Hyperhidrosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nivobotulinumtoxin A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nivobotulinumtoxin A overview

NivobotulinumtoxinA/Botulinum Toxin Type A (Meditoxin/Botulift/ Coretox) is a neuromuscular agent which is produced from fermentation of Hall strain Clostridium botulinum type A. It is formulated as powder for solution for intramuscular route of administration. NivobotulinumtoxinA/ is indicated for the treatment of benign essential blepharospasm, Hemifacial spasm, cerebral palsy and upper limb muscle spasticity.

MT-10109 (nivobotulinumtoxinA) is under development for the treatment of cervical dystonia (neck dystonia, spasmodic torticollis), benign masseteric hypertrophy, primary axillary hyperhidrosis, unspecified musculoskeletal disorders and benign essential blepharospasm. It is administered through intradermal, intradetrusor routes. It was also under development for the treatment of neuropathic pain in patients with diabetic peripheral polyneuropathy, migraine, overactive bladder.

AbbVie overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

For a complete picture of Nivobotulinumtoxin A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.